Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys' Q4 Sales Rise 44 Percent as Profit Turns to Loss on R&D, Restructuring Costs

NEW YORK (GenomeWeb News) — MorphoSys today said fourth-quarter revenues increased 44 percent as operating expenses, coming largely from R&D, spiked 115 percent and profit turned to a loss.
Total receipts for the three months ended Dec. 31, 2006, increased to €14 million ($18.5 million) from €9.7 million year over year.
MorphoSys said operating expenses increased to €15.7 million from €7.3 million year over year. The increase “was mainly due to higher product and technology development, in addition to restructuring costs in the UK.”
The company posted a €100,000 loss for the quarter compared with an €800,000 profit in the year-ago period.
MorphoSys said it had around €66 million in cash, cash equivalents, and available-for-sale financial assets as of Dec. 31.
MorphoSys said it expects 2007 revenues for the MophoSys Group of between €7 million and €10 million, with roughly two-thirds coming from its Therapeutic Antibodies segment.
In January, MorphoSys purchased the UK antibody supplier Serotec for £20 million. The deal expanded the company’s antibody business and gives MorphoSys distribution channels in the UK, US, France, and Scandinavia.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.